Related news:Stocks making the biggest moves midday: Sarepta Therapeutics, Hertz Global, Asana and more - Stocks making the biggest moves premarket: Gilead Sciences, Sarepta Therapeutics, Nike and more
Sarepta Therapeutics
Bookmark
ShareSarepta Therapeutics is a company. It is located in Cambridge, the United States. The company is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Cambridge
- state: MA
- country: United States
- sector: Health Care
- industry: Biotechnology
- CEO: Douglas S. Ingram Esq.
- CEO gender: Male
Classified as: organization
Business
Sarepta Therapeutics is one of the companies in the United States, companies in Biotechnology, companies in Health Care and 3,466,499 companies in our database.
- Assets: 3.1B $
- Debt: 1.2B $
- Employees: 840 people
- Free cash flow: 54M $
- Market cap: 9.8B $
- Profits: -418780000 $
- Revenues: 765.8M $
Stocks from Sarepta Therapeutics:
Talking Points:
- Sarepta Therapeutics | Biopharmaceutical Company for Rare Diseases
- We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. Learn more about Sarepta.
- Commercial-stage biopharma company focused on the discovery & development of precision genetic medicine to treat rare neuromuscular diseases. https:
- t.co
- HFP4txOCxe
- Dragging Tomorrow Into Today. | Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a global biotechnology company on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular ...
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Learn more about talking points
